Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Niclosamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.89 |
| ▸ | MAPT | P10636 | 4/20 | 0.89 |
| ▸ | MEN1 | O00255 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | HTT | P42858 | 2/20 | 0.89 |
| ▸ | RAB9A | P51151 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | AURKA | O14965 | 1/20 | 0.89 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.89 |
| ▸ | JAK2 | O60674 | 1/20 | 0.89 |
| ▸ | GMNN | O75496 | 1/20 | 0.89 |
| ▸ | EGFR | P00533 | 1/20 | 0.89 |
| ▸ | TP53 | P04637 | 1/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | LYN | P07948 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niclosamide SCHEMBL16686086 | 0.94 | KMT2A (0.95) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL6662409 | 0.94 | KMT2A (1.00) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL67182 | 0.94 | KMT2A (1.00) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL29363878 | 0.94 | KMT2A (1.00) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL28313524 | 0.94 | KMT2A (1.00) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL27365268 | 0.94 | KMT2A (1.00) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL2061202 | 0.93 | KMT2A (0.97) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL31098821 | 0.93 | KMT2A (0.97) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL27937315 | 0.93 | KMT2A (0.97) | KMT2AMAPTMEN1SMN1; SMN2NPC1 | |
| Niclosamide SCHEMBL1526777 | 0.92 | KMT2A (0.95) | KMT2AMAPTMEN1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210677-A1 | NICLOSAMIDE PARTICLES AND USES THEREOF | Crititech, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022055958-A1 | NICLOSAMIDE PARTICLES AND USES THEREOF | CRITITECH, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-106070190-A | Two-in-one \" Lac Bovis seu Bubali shape \" pesticide of a kind of efficient stable and the preparation of compounding suspending agent thereof | 杨美玲 | 2016-11-09 | — | — | CN | disclosed |
| US-8148328-B2 | Salicylanilides enhance oral delivery of therapeutic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| EP-2182956-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | The Regents of the University of California (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2049137-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | The Regents of the University of California (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009032749-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008021088-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | DNPEP, NGLY1, VIP | KMT2A 3301/4885MAPT 2381/4885MEN1 3158/4885 |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | KMT2A 2123/4885MAPT 3372/4885MEN1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.